Package Leaflet: Information for the User
Sumatriptan Klaria 27 mg Buccal Film
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Sumatriptan Klaria belongs to a group of medicines called triptans (also known as 5-HT1 receptor agonists), which are used to treat migraine.
Migraine symptoms may be caused by the temporary expansion of blood vessels in the head. It is believed that Sumatriptan Klaria reduces the dilation of these blood vessels. This, in turn, helps to eliminate the headache and alleviate other symptoms of a migraine episode, such as nausea or vomiting and sensitivity to light and sound.
Sumatriptan Klaria only works when a migraine attack has started. It will not prevent an attack from happening.
You should not use sumatriptan to prevent a migraine episode.
Do not take Sumatriptan Klaria
If any of these apply to you:
→ Tell your doctor before taking Sumatriptan Klaria.
Warnings and precautions
Talk to your doctor or pharmacist before taking Sumatriptan Klaria.
In very rare cases, people have developed serious heart problems after using sumatriptan, even though they had no previous symptoms of heart disease. If you think you may be in one of these situations, it could mean that you have a higher risk of developing heart disease, so:
→ Tell your doctor so that they can monitor your heart function before prescribing Sumatriptan Klaria.
If you have a history of seizures
Or if you have other conditions that may make it more likely that you will have a seizure, for example, a head injury or if you have a history of alcoholism.
If you have liver or kidney disease
→ Tell your doctor so that they can monitor you more closely.
If you are allergic to antibiotics called sulfonamides
If this is the case, you may also be allergic to Sumatriptan Klaria. If you know you are allergic to an antibiotic but are not sure if it is a sulfonamide:
→ Tell your doctor or pharmacist before using Sumatriptan Klaria.
If you are taking antidepressants called SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin and norepinephrine reuptake inhibitors)
→ Tell your doctor or pharmacist before using Sumatriptan Klaria. Also, see the section "Other medicines and Sumatriptan Klaria" below.
If you use Sumatriptan Klaria frequently
Taking Sumatriptan Klaria too often can make your headaches worse.
→ Tell your doctor if this is the case. They may advise you to stop using Sumatriptan Klaria.
If you experience pain or pressure in your chest after using Sumatriptan Klaria
These effects can be intense, but they usually go away quickly. If they do not go away quickly or get worse:
→ Seek medical attention immediately. You can find more information about these possible side effects in section 4 of this leaflet.
Other medicines and Sumatriptan Klaria
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
Some medicines must not be taken with Sumatriptan Klaria and others may cause side effects if taken with Sumatriptan Klaria. You must tell your doctor if you are taking:
Pregnancy, breastfeeding, and fertility
Driving and using machines
Migraine symptoms or your medicine may make you feel drowsy. If this happens to you, do not drive or operate machinery.
Taking sumatriptan can cause symptoms such as dizziness and weakness, which can negatively affect your reaction time. Wait until you know how sumatriptan affects you before driving or operating machinery.
Sumatriptan Klaria contains sorbitol
This medicine contains 9.6 mg of sorbitol in each 27 mg buccal film.
Sumatriptan Klaria contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially "sodium-free".
Use Sumatriptan Klaria only after your migraine has started.
Do not use Sumatriptan Klaria to try to prevent an episode.
Follow the instructions for taking this medicine exactly as your doctor or pharmacist has told you. If you are unsure, ask your doctor or pharmacist again.
The recommended dose is:
Adults (18 to 65 years old):
The usual dose for adults aged 18 to 65 years is one 27 mg Sumatriptan Klaria buccal film. Do not use more than two buccal films in 24 hours.
Adolescents (12 to 17 years old):
Sumatriptan Klaria buccal film is not recommended for adolescents due to the lack of a lower concentration.
Children (under 12 years old):
Sumatriptan Klaria is not recommended for children under 12 years old.
Older people (over 65 years old):
Sumatriptan Klaria is not recommended for people over 65 years old.
Method of administration
The film will dissolve completely within 20 minutes. Once the film has dissolved, there will be nothing left in your mouth.
Do not chew or swallow the film. The buccal film does not need to be taken with liquid. It can be used in situations where liquids are not available. Buccal films can also be beneficial if you experience nausea or cannot drink during a migraine episode, or if you do not like swallowing conventional tablets.
When to use Sumatriptan Klaria
It is best to use Sumatriptan Klaria as soon as you feel a migraine episode starting, although it can be used at any time during an episode.
What to do if symptoms come back
You can use a second Sumatriptan Klaria buccal film after 2 hours, but do not use more than two buccal films in 24 hours.
If the first buccal film has no effect
→ Consult your doctor or pharmacist, they will advise you.
If you take more Sumatriptan Klaria than you should
→ Contact your doctor, they will advise you.
In case of overdose, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medicine and the amount taken.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some symptoms may be caused by the migraine itself.
Allergic reaction: seek medical attention immediately
The following side effects have occurred, but their exact frequency is unknown.
Common(may affect up to 1 in 10 people):
Other common side effects include:
Very rare(may affect up to 1 in 10,000 people):
Some patients may have the following side effects with a frequency that is
not known
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Medicines Monitoring System for Human Use: https://www.notificaram.es
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Store in the original packaging to protect from light.
Do not use this medicine after the expiry date stated on the packaging after EXP. The expiry date is the last day of the month indicated.
Do not use this medicine if you notice visible signs of deterioration.
Medicines should not be disposed of via wastewater or household waste. Return the packaging and any unused medicine to the pharmacy. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Composition of Sumatriptan Klaria
Appearance of the product and packaging
Buccal film. The 27 mg buccal film is rectangular (25 x 20 mm) and has an approximate thickness of 150 μm. The soft and flexible film is between transparent and opaque, between yellow and orange-brown, with a smooth and flat surface.
Sumatriptan Klaria 27 mg buccal film is available in packs of 2 and 6 sachets, each containing one buccal film.
Marketing authorisation holder and manufacturer
Marketing authorisation holder
Klaria AB
Virdings allé 2
754 50 Uppsala
Sweden
Manufacturer
AdhexPharma SAS
42/44 Rue de Longvic
21300 Chenôve
France
This medicine has been authorised in the Member States of the European Economic Area under the following names:
Germany Sumatriptan Klaria 27 mg Buccalfilm
Italy Sumatriptan Klaria
Spain Sumatriptán Klaria 27 mg buccal film
Date of last revision of this leaflet: 08/2024The detailed information of this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/)